When was AeroRx founded?

AeroRx was founded in 2023 and raised its 1st funding round 2 years after it was founded.

Where is AeroRx located?

AeroRx is headquartered in La Jolla, United States.

How many employees does AeroRx have?

As of Sep 30, 2026, the latest employee count at AeroRx is 3.

Is AeroRx a funded company?

AeroRx is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Sep 25, 2025.

When was the latest funding round of AeroRx?

AeroRx's latest funding was a $***** Series A round on Sep 25, 2025, with participation from 3 investors. Its primary sector is Pulmonology. In United States, the Pulmonology sector has seen $990M in funding in 2026 to date.

Where does AeroRx rank among its competitors?

AeroRx ranks 8th amongst 23 active competitors, of which 10 are funded. It stands 7th in terms of total funding among its competitors. The most recent competitor to raise funding was Expedition Therapeutics, which secured $115M in Aug, 2026.

Who are the top competitors of AeroRx?

AeroRx's top competitors include Theravance Biopharma, MediciNova and Expedition Therapeutics. Among them, Expedition Therapeutics secured the most recent funding round in August, 2026.

AeroRx - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of nebulized combination drug therapies for respiratory diseases. The company focuses on creating treatments for Chronic Obstructive Pulmonary Disease, particularly in older patients. Their approach involves combining multiple medications into a single nebulized therapy. This aims to improve treatment effectiveness and convenience for patients with respiratory conditions. The company targets the specific needs of the aging population facing respiratory challenges.

Website: aerorxtx.com
Email ID: *****@aerorxtherapeutics.com
Phone Number: +1 **********

Key Metrics

Founded Year

2023

Location

La Jolla, United States

Stage

Series A

Total Funding

$21M in 1 round

Latest Funding Round

Series A, Sep 25, 2025, $*****

Investors

Avalon Bio Ventures & 2 more

Ranked

8^th among 23 active competitors

Employee Count

3 as on Sep 30, 2026

Similar Companies

Theravance Biopharma & 23 more

View AeroRx's full profile

AeroRx has raised a total funding of $21M over 1 round. Its latest funding round was a Series A round on Sep 25, 2025 for $*****. 3 investors participated in its latest round. AeroRx has 3 institutional investors.

Here is the list of recent funding rounds of AeroRx:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 25, 2025	4815374	Series A	4460983	9926085	7206667	9249515

Access funding benchmarks and valuations. Sign up today!

View details of AeroRx's funding rounds and investors

The founders of AeroRx are Mei-chang Kuo and Mei Chang Kuo.

Here are the details of AeroRx's key team members:

Mei-chang Kuo: Co-Founder of AeroRx.
Mei Chang Kuo: Co-Founder of AeroRx.

View details of AeroRx's Founder profiles and Board Members

AeroRx's employee count trend

AeroRx has 3 employees as of Sep 26. Here is AeroRx's employee count trend over the years:

Uncover AeroRx's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AeroRx include Theravance Biopharma, MediciNova and Expedition Therapeutics. Here is the list of Top 10 competitors of AeroRx, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Theravance Biopharma 2001, Francisco (United States), Public	Developer of therapeutics for inflammatory and immunological diseases	-	Sierra Ventures, Acorn Bioventures & 6 others	64/100
2nd	MediciNova 2000, San Diego (United States), Public	Developer of small molecule for the treatment of acute exacerbations of asthma and COPD	$83.9M	JAFCO Group, Aspire Capital & 15 others	59/100
3rd	Expedition Therapeutics 2024, San Francisco (United States), Series B	Developer of treatments targeting inflammatory and respiratory diseases for patient care	$280M	General Atlantic, Novo Holdings & 12 others	56/100
4th	Altesa Biosciences 2020, College Park (United States), Series B	Developer of drugs to treat RNA viruses	$110M	Forbion, Atlantic Partners & 4 others	56/100
5th	ZEO ScientifiX 2011, Fort Lauderdale (United States), Seed	Biopharmaceutical company focused on researching novel biological therapeutics	$1M	-	52/100
6th	ReAlta Life Sciences 2018, Norfolk (United States), Series C	Developer of therapeutic drugs for acute inflammatory and rare diseases	$150M	Marathon Pharma	51/100
7th	TFF Pharmaceuticals 2018, Austin (United States), Public	Developer of inhalation products for chronic respiratory diseases	$22.2M	Liquid Venture Partners, NIAID & 2 others	51/100
8th	AeroRx 2023, La Jolla (United States), Series A	Developer of nebulized combination drug therapies for respiratory diseases	$21M	Alexandria, Correlation Ventures & 1 others	42/100
9th	Tessel Bio 2021, Cambridge (United States), Funding Raised	Pharmaceutical development firm harnessing the power of human physiology to discover new drugs	-	E14 Fund, Sarah Smith Fund	40/100
10th	Elevation Pharmaceuticals 2007, San Diego (United States), Acquired	Developer of aerosol drug products for COPD patients	$77M	Canaan, Care Capital & 3 others	36/100